Antiestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial. In this study, we performed a kinase inhibitor screen on antiestrogen responsive MCF-7 cells and a panel of MCF-7-derived tamoxifen-and fulvestrant-resistant cell lines. Our focus was to identify common and distinct molecular mechanisms involved in tamoxifen-and fulvestrant-resistant cell growth. We identified 18 inhibitors, of which the majority was common for both tamoxifen-and fulvestrant-resistant cell lines. Two compounds, WP1130 and JNJ-7706621, exhibiting prominent preferential growth inhibition of antiestrogen-resistant cell lines, were selected for further studies. WP1130, a deubiquitinase inhibitor, induced caspase-mediated cell death in both tamoxifen-and fulvestrant-resistant cell lines by destabilization of the anti-apoptotic protein Mcl-1. Mcl-1 expression was found upregulated in the antiestrogen-resistant cell lines and depletion of Mcl-1 in resistant cells caused decreased viability. JNJ-7706621, a dual Aurora kinase and cyclin-dependent kinase inhibitor, specifically inhibited growth and caused G2 phase cell cycle arrest of the tamoxifen-resistant cell lines. Knockdown studies showed that Aurora kinase A is essential for growth of the tamoxifen-resistant cells and inhibition of Aurora kinase A resensitized tamoxifen-resistant cells to tamoxifen treatment. Preferential growth inhibition by WP1130 and JNJ-7706621 was also found in T47D-derived tamoxifen-resistant cell lines, pointing at Mcl-1 and Aurora kinase A as potential treatment targets. In addition, tumor samples from 244 estrogen receptor-positive breast cancer patients treated with adjuvant tamoxifen showed that higher expression level of Aurora kinase A was significantly associated with shorter disease-free and overall survival, demonstrating the potential of Aurora kinase A as a biomarker for tamoxifen resistance.
INTRODUCTION
The antiestrogens tamoxifen and fulvestrant are used for the treatment of estrogen receptor α-positive (ER+) breast cancer. 1 Tamoxifen is a selective ER modulator with partial ER agonistic activity, whereas fulvestrant is a selective ER down modulator with pure ER antagonistic activity. 2 Although aromatase inhibitors have now replaced tamoxifen as the standard treatment for postmenopausal breast cancer patients, tamoxifen remains the standard firstline endocrine therapy for premenopausal patients. Fulvestrant was introduced in the clinic as a therapeutic option for patients who relapse on tamoxifen or aromatase inhibitor treatment. 3 Development of drug resistance is a major cause of treatment failure in breast cancer. Within the first 15 years after surgery, relapse occurs in about one-third of patients receiving adjuvant tamoxifen treatment, 1 whereas almost all patients receiving tamoxifen for advanced disease eventually develop resistance. Resistance to endocrine therapy is complex and presumably caused by multifactorial molecular changes. 4 Despite intensive research, it is still unclear, which signaling pathways are the major drivers of resistance. Clinical data demonstrate reduced response to endocrine therapy in tumors with epidermal growth factor receptor 2 (ERBB2/HER2) amplification; 5, 6 however, a study comparing primary tumors and corresponding recurrent tamoxifen-resistant tumors showed that only 6% had acquired HER2 amplification, indicating that gain of HER2 overexpression is an infrequent event in acquired tamoxifen resistance. 7 When comparing primary tumors with metastatic tumors from breast cancer patients, who had recurred on tamoxifen treatment, we observed increased activation of EGFR and HER3, but not HER2, on acquisition of tamoxifen resistance 8 and similar observations were made in our cell culture models for both acquired tamoxifen and fulvestrant resistance. [9] [10] [11] Apart from HER receptors, other signaling pathways also seem to contribute to growth and survival of tamoxifen-resistant breast cancer cells, including ER signaling. 4, 11, 12 ER-associated proteins, for example, the forkhead protein FOXA1, are essential players in tamoxifen resistance 13 and ER-binding profiles can predict outcome in ER+ patients. 14 Most patients, who have relapsed on tamoxifen therapy, maintain ER expression in the tumor and may benefit from fulvestrant therapy. 15, 16 However, the majority of these patients eventually relapse on the second-line fulvestrant therapy, 16 highlighting the need for new treatment options for tamoxifen-and fulvestrant-resistant breast cancer.
Identification of molecular mechanisms underlying tamoxifen and fulvestrant resistance may open new windows for the rational design of therapies to overcome treatment failure and for discovery of new biomarkers for antiestrogen resistance. As emerging evidence particularly points to signaling from protein kinase pathways as drivers of antiestrogen-resistant cell growth, 4 we conducted a functional kinase inhibitor screen to identify novel therapeutic targets for tamoxifen and fulvestrant resistance. Our findings demonstrate that tamoxifen-and fulvestrantresistant cells share common traits but also utilize different growth signaling pathways and suggest that Mcl-1 may be a novel therapeutic target in antiestrogen-resistant breast cancer, whereas Aurora kinase A may be both a novel therapeutic target and a potential biomarker for tamoxifen resistance.
RESULTS

Kinase inhibitor screen identifies compounds preferentially inhibiting the growth of tamoxifen-and fulvestrant-resistant breast cancer cell lines
To identify the potential molecular mechanisms conferring tamoxifen and fulvestrant resistance in breast cancer, we used a kinase inhibitor screen comprising a library of 195 inhibitors each targeting one to several protein kinases. The screen was performed in the parental antiestrogen-sensitive breast cancer cell line MCF-7, four different tamoxifen-resistant (TAM R -1, TAM R -4, TAM R -7 and TAM R -8) and four different fulvestrant-resistant (164 R -5, 164 R -7, 182 R -1 and 182 R -6) cell lines (Figure 1a ). The results from the screen are represented as volcano plots displaying the statistical significance against the growth inhibition in the resistant cell lines relative to MCF-7 for each of the kinase inhibitors ( Figure 1b ). We selected inhibitors that resulted in ratios were seeded in 96-well plates and treated in triplicate with a kinase inhibitor library, comprising 195 different compounds. After 5 days of exposure to 1 μM kinase inhibitor, cell number was assessed using CellTiter-Glo Luminescent Cell Viability Assay. (b) Volcano plots were generated by plotting the growth inhibitory effects in the resistant cell lines relative to MCF-7 cells against the P-values from t-test comparison of the effect on resistant cell lines versus MCF-7. Using a twofold cutoff value for the relative growth inhibition and a P-value o0.05, candidate kinase inhibitors (hits) were identified, shown in the upper right corner indicated by the blue lines. The inhibitors WP1130 and JNJ-7706621 are shown in the figure.
of at least 2.0 and P-values o0.05. A total of 18 different inhibitors fulfilled these criteria (listed in Supplementary Table S1 ). Of these, seven compounds were identified in at least two tamoxifenresistant and two fulvestrant-resistant cells lines, and three compounds were identified in all four tamoxifen-resistant cell lines and none of the fulvestrant-resistant cell lines (Table 1) , whereas no inhibitors were exclusively identified in all four fulvestrant-resistant cell lines. The results suggest the existence of both common and tamoxifen-specific resistance mechanisms. The majority of the hits targeted the HER receptors or their downstream signaling pathways, confirming our previous findings that HER receptor signaling has an important role in antiestrogen resistance. 9, 11, [17] [18] [19] The inhibitors WP1130 and JNJ-7706621 were selected for further analysis as they exhibited very pronounced preferential growth inhibition of the antiestrogen-resistant cell lines ( Supplementary Table S1 ).
WP1130 downregulates Mcl-1 and induces apoptosis of antiestrogen-resistant cell lines
Dose-response growth assays in MCF-7 and four representative antiestrogen-resistant cell lines TAM R -1, TAM R -4, 164 R -7 and 182 R -6 validated the preferential growth inhibitory effect of the deubiquitinase inhibitor WP1130 (Figure 2a ). On treatment with 1 μM WP1130, antiestrogen-resistant cell lines displayed significantly increased cell death compared with MCF-7 ( Figure 2b ). The caspase inhibitor z-VAD-fmk was found to partially protect cells against WP1130-induced death (Supplementary Figure S1a) , indicating that WP1130 induces caspase-mediated apoptosis, as also described by others. 20 In support of this, we observed PARP cleavage after WP1130 treatment in the antiestrogen-resistant cell lines but not in MCF-7 ( Figure 2c ). As it has been published that WP1130 causes destabilization of the anti-apoptotic protein Mcl-1 in leukemia cells, 21 The Aurora kinase inhibitor JNJ-7706621 induces apoptotic cell death in tamoxifen-resistant cell lines The Aurora kinase and cell cycle-dependent kinase (CDK) inhibitor JNJ-7706621 was identified in the screen to exert pronounced preferential growth inhibition of tamoxifen-resistant cell lines ( Supplementary Table S1 ). Dose-response growth experiments showed that tamoxifen-resistant cell lines, but not fulvestrantresistant cell lines, were more sensitive to JNJ-7706621 treatment than MCF-7 cells (Figure 4a ). JNJ-7706621 induced distinct cell death in the tamoxifen-resistant cells, whereas MCF-7 cells were unaffected ( Figure 4b ). The JNJ-7706621-induced cell death was caspase dependent (Supplementary Figure S2b ), indicative of apoptosis. Western blot analyses revealed that treatment of TAM R -1 and TAM R -4 with JNJ-7706621 for up to 24 h resulted in unchanged, or slightly reduced, levels of Aurora kinases A and B, followed by an increase at 48 h. MCF-7 cells also displayed higher levels of both Aurora kinases after 48 h, but the level was lower than in the resistant cell lines (Figure 4c ). JNJ-7706621 has been shown to cause cell cycle arrest in G2/M. 27 We observed that the G2/M specific cyclin B1 and the anti-apoptotic protein survivin, which is expressed during G2/M phase, 28 were upregulated after 48 h in the tamoxifen-resistant cell lines, whereas no major change was observed in MCF-7 ( Figure 4c ). Furthermore, the forkhead protein FOXA1, which is involved in tamoxifen-resistant cell Abbreviations: DUB, deubiquitinase; EGFR, epidermal growth factor receptor; mTOR, mammalian target of rapamycin; PDGFR; plateletderived growth factor receptor; PKC, protein kinase C; PI3K, phosphatidylinositol 3-kinase; VEGFR, vascular endothelial growth factor receptor. Hits were selected using the following criteria; growth inhibition relative to MCF-7 cells 42.0 and P-value o0.05. Common hits were defined as hits identified in at least two tamoxifen-resistant and two fulvestrant-resistant cell lines. Tamoxifen resistance hits were identified in all four tamoxifenresistant cell lines and none of the fulvestrant-resistant cell lines.
growth, 13 was clearly reduced on treatment with JNJ-7706621 in the tamoxifen-resistant cell lines, whereas remaining largely unchanged in MCF-7 cells ( Figure 4c ). Together, these data indicate that JNJ-7706621 treatment induces arrest in G2/M phase and apoptotic cell death.
JNJ-7706621 causes G2 arrest in tamoxifen-resistant cell lines Next, we investigated the effect of JNJ-7706621 on the cell cycle phase distribution. Treatment for up to 48 h with 1 μM JNJ-7706621 caused arrest in the G2/M phase in the tamoxifen-resistant cell lines TAM R -1 and TAM R -4, whereas MCF-7 exhibited minor changes in cell cycle phase distribution (Figure 5a and Supplementary Figure S2a ).
To determine whether treatment with JNJ-7706621 caused accumulation in G2 or M phase, we analyzed mitosis-specific Histone-H3 Ser10-phosphorylation 29 performed with tamoxifen and 4-OH-tamoxifen (Figures 7a and b ). Both resistant cell lines showed no response, confirming the resistant phenotype, whereas T47D responded in a dosedependent manner. Furthermore, the tamoxifen-resistant T47D cell lines partially responded to treatment with increasing doses of fulvestrant (Figure 7c ), similar to the MCF-7-based tamoxifenresistant cell lines. 11 The cell lines were treated with the inhibitors WP1130 and JNJ-7706621 in concentrations corresponding to those used in the assays performed in the MCF-7-based cell lines. Both compounds proved to significantly inhibit the growth of the T47D-based tamoxifen-resistant cell lines compared with the parental T47D cell line (Figures 7d and e) .
In resemblance to the MCF-7-derived tamoxifen-resistant cell lines, T47D-derived tamoxifen-resistant cell lines retained ER expression ( Figure 7f ). Although PgR expression is not detectable in MCF-7-derived tamoxifen-resistant cell lines, 31 PgR expression was reduced but not lost in T47D-derived cell lines. Bcl-2 expression appeared to be largely unchanged. Of interest, Mcl-1 was upregulated in the T47D-derived tamoxifen-resistant cell lines (Figure 7f ) as in the MCF-7-based antiestrogen-resistant cell lines (Figure 2d) . Thus, the T47D-derived tamoxifen-resistant cell lines confirm the validity of WP1130 and JNJ-7706621 as potential therapeutic compounds.
Aurora kinase A has potential as a biomarker for tamoxifen resistance We performed immunohistochemical analysis on tumor samples from 244 high-risk ER-positive breast cancer patients, who had received tamoxifen as first-line adjuvant endocrine treatment. Clinical and pathological data from the patients have previously been published. 8 Aurora kinase A protein expression was found in 72% of the tumors and confined to the cytoplasm and nucleus of invasive breast cancer cells (Figure 8a ). Aurora kinase A was scored as percentage positive tumor cells. Univariate analysis revealed significant association between higher expression level of Aurora kinase A and shorter disease-free and overall survival (P = 0.0078 and P = 0.0011, respectively). In multivariate analysis including the standard covariates-tumor grade, size and nodal status-high Aurora kinase A expression was a significant and independent predictor of shorter disease-free survival (P = 0.0062). Kaplan-Meier plots were generated for Aurora kinase A expression levels divided into negative/weak (less than 1% positive cancer cells), moderate (1-3% positive cancer cells) and high (above 3% positive cancer cells) staining and log-rank testing revealed a statistically significant association between Aurora kinase A expression level and both disease-free survival (P = 0.0097) and overall survival (P = 0.0383; Figures 8b and c) .
DISCUSSION
Resistance to antiestrogens is a major challenge in current breast cancer treatment. Using cell-based models of resistance against the most commonly used antiestrogens, tamoxifen and fulvestrant, we identified Mcl-1 and Aurora kinase A as potential novel therapeutic targets in antiestrogen-resistant breast cancer and demonstrated the potential of Aurora kinase A as a biomarker for tamoxifen resistance. In our kinase inhibitor screen, we identified several inhibitors affecting growth of both tamoxifen-and fulvestrant-resistant breast cancer cell lines, pointing to the existence of common resistance mechanisms, such as signaling from HER receptors and their downstream kinases, thus supporting previous investigations. [8] [9] [10] [11] 32, 33 WP1130 resulted in substantial growth inhibition of the majority of tamoxifen-and fulvestrant-resistant cell lines, but exerted only modest effect on parental MCF-7 cells, suggesting that WP1130 targets one of the key signaling pathways in tamoxifen-and fulvestrant-resistant cells. WP1130 has been described to cause the degradation of Mcl-1 by inhibition of the deubiquitinase USP9x in chronic myeloid leukemia cells causing apoptosis. 20, 21, 34 Similar to these observations, we report that WP1130 resulted in the downregulation of Mcl-1 and induction of apoptosis in antiestrogen-resistant cells. We noted that Mcl-1 was expressed at a higher level in MCF-7-and T47D-derived antiestrogen-resistant cell lines compared with their parental cell lines. These results suggest that although Bcl-2 provides estrogen-mediated survival signaling in antiestrogen-sensitive cells, 35 antiestrogen-resistant cells may also use Mcl-1 for cell survival. In agreement with this, depletion of Mcl-1 was sufficient to decrease the viability of antiestrogen-resistant cells. Mcl-1 expression is regulated by different signaling molecules, including NFκB, 36 PI3K/Akt 37 and ERK. 38 It could be speculated that the increased expression of Mcl-1 in the antiestrogen-resistant cell lines is linked to the previously shown elevated signaling through Akt, ERK and NFκB. 9, 11, 12, 18 Mcl-1 regulates drug response in cancer cells through its antiapoptotic function, and it has been demonstrated that Mcl-1 can contribute to resistance against several drug types, including herceptin and chemotherapy. 38, 39 Mcl-1 is elevated in various tumor types, including breast cancer and high expression of Mcl-1 has been correlated with high tumor grade and poor prognosis in breast cancer patients. 40 However, we could not demonstrate the 41 and our data suggest that Mcl-1 may be a target for treatment for both tamoxifen-and fulvestrant-resistant breast cancer. The Aurora kinase and CDK inhibitor JNJ-7706621 was identified in the kinase inhibitor screen to target tamoxifen-resistant but not fulvestrant-resistant cell lines. Aurora kinases promote cell cycle progression by regulating mitotic events-Aurora kinase A by regulating processes such as chromosome maturation, spindle assembly and mitotic entry, whereas Aurora kinase B ensures correct chromosomal segregation during cytokinesis and regulation of the mitotic checkpoint. 30 We show here that the depletion of Aurora kinase A, but not B, caused cell cycle arrest in G2/M phase, similar to other studies showing that although Aurora kinase B inhibition overrides the mitotic checkpoint and drives cells through aberrant mitosis, 42 Aurora kinase A inhibition causes cell cycle arrest. 43 Phosphorylation of Histone H3 at Ser10 is a crucial event for the onset of mitosis, 29 which is mediated by Aurora kinase B and possibly also Aurora kinase A. 44 Treatment of MCF-7 and tamoxifen-resistant cells with JNJ-7706621 for 24 h blocked Histone H3 phosphorylation and mitotic entry, presumably reflecting suppressed Aurora kinase activity. After 48 h of JNJ-7706621 treatment, MCF-7 cells had entered mitosis and resumed cell cycle, wherease tamoxifen-resistant cells remained arrested in the G2 cell cycle phase, suggesting that tamoxifenresistant cells, in contrast to MCF-7, are unable to overcome the block in G2/M transition on JNJ-7706621 treatment. Depletion of Aurora kinase A resulted in substantial growth inhibition of tamoxifen-resistant cells, suggesting that Aurora kinase A is a treatment target in tamoxifen resistance. Several ongoing clinical trials are currently evaluating the potential of Aurora kinase inhibitors in cancer treatment. 30, 45 The finding that tamoxifen-and fulvestrant-resistant cell lines utilize common signaling pathways and that tamoxifen-resistant cell lines also have specific signaling pathways is in agreement with our previously published data showing that ligandindependent activation of ER is important for growth of tamoxifen-resistant cells. 11, 46 In fulvestrant-resistant cell lines, binding of fulvestrant results in ER degradation, and thus ligandindependent ER activation through cross-talk with growth factor signaling pathways is not an option. Our data suggest that Mcl-1 and Aurora kinase A may represent independent mechanisms underlying antiestrogen resistance. Although we have observed that treatment with JNJ-7706621, at concentrations which induced apoptosis, also reduced the level of Mcl-1 protein in tamoxifen-resistant cells (Supplementary Figure S2c) , this is likely due to Mcl-1 being a cleavage target of caspases during apoptosis. 47 Importantly, the inhibition of Aurora kinase A resensitized tamoxifen-resistant cells to tamoxifen treatment, whereas this was not observed on inhibition of Mcl-1 ( Supplementary Figures S1c and d) . Thus, Mcl-1 presumably works through an ER-independent mechanism, whereas our data indicate that Aurora kinase A causes tamoxifen resistance through ER. Clinical data have shown that the prognostic significance of Aurora kinase A was limited to ER+ breast cancer, suggesting a link between Aurora kinase A and ER. 48 In support of this, Aurora kinase A has been shown to phosphorylate ER at Ser167/Ser305, leading to increased ER transactivation and decreased tamoxifen sensitivity. 49 We observed that the ER pioneer factor FOXA1, which is required for ER signaling in tamoxifen-resistant cells, 13 was decreased on treatment with the Aurora kinase inhibitor JNJ-7706621 in tamoxifen-resistant cells, indicating that ER signaling was impaired in these cells.
Our immunohistochemical analyses on primary breast tumors from patients who had received adjuvant tamoxifen therapy revealed a significant association between higher Aurora kinase A expression and shorter time to recurrence and death. These data are in compliance with recently published data showing that elevated Aurora kinase A expression was significantly associated with recurrence in ER-positive tumors. [48] [49] [50] Our finding that high Aurora kinase A expression is an independent predictor of recurrence in tamoxifen-treated breast cancer patients merits further investigation of Aurora kinase A as a new potential biomarker for tamoxifen resistance. , MCF-7/182 R -1 (182 R -1) and MCF-7/182 R -6 (182 R -6) by long-term treatment with 100 nM fulvestrant (ICI182 780; Tocris Bioscience, Bristol, UK) as previously described. 24, 31 The T47D/S2 (T47D) cell line was adapted to grow in medium with 2% fetal calf serum and used for establishing tamoxifen-resistant cell lines T47D/TR-1 and T47D/TR-2 by long-term treatment with 1 μM tamoxifen. Clonal selection was performed in medium without tamoxifen. After further 10 months in the presence of tamoxifen, the growth rate of the resistant cell lines had increased to a similar level as the parental cell line. MCF-7based cell lines were cultured in phenol red-free DMEM/F12 medium containing 1% fetal calf serum, 2.5 mM L-glutamax and 6 ng/ml insulin. T47D-based cell lines were cultured in phenol red-free RPMI1640 medium containing 2% fetal calf serum, 2.5 mM L-glutamax and 8 μg/ml insulin. Medium for resistant cell lines was routinely supplemented with 1 μM tamoxifen or 100 nM fulvestrant.
MATERIALS AND METHODS
Kinase inhibitor screen
The kinase inhibitor library was purchased from Selleck Chemicals (Houston, TX, USA). Cells were seeded in triplicate in 96-well plates using standard growth medium and allowed to adhere before treatment for 5 days with 1 μM inhibitor. Dimethyl sulfoxide (0.1%) treated controls were included in each plate. Cell viability was assayed using CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA) and measured using Varioscan Flash platereader (Thermo Scientific, Waltham, MA, USA).
Cell growth and cytotoxicity assays
Assays were performed in 96-well plates. Cells were seeded in standard growth medium and treated with WP1130, JNJ-7706621 (Selleck Chemicals) or MIM1 (Millipore, Billerica, MA, USA). Cell number was determined by crystal violet staining as previously described. 52 Cytotoxicity was measured using lactate dehydrogenase cytotoxicity assay (Roche, Basel, Switzerland) according to the manufacturer's instructions. All experiments were repeated at least twice with similar results.
Western blot analyses
Western blotting was performed as described before. 11 Antibodies targeting the following proteins were used: Aurora kinase A (4718), Aurora . Cells were transfected as described above using 1 μg vector construct in combination with 10 nM control siRNA (Sigma-Aldrich) or 10 nM Mcl-1 3′-UTR targeting siRNA. 53 Cell growth assays were performed as described above 4 days after transfection.
Flow cytometry
Cells were fixed with ethanol, stained with 20 μg/ml propidium iodide and treated with 40 μg/ml RNaseA as previously described. 54 For analysis of phospho-Histone-H3, cells were fixed in 2% formaldehyde, permeabilized in ethanol, blocked in 0.5% bovine serum albumin/phosphate-buffered saline and incubated with AlexaFluor488-conjugated phospho-S10-Histone-H3 antibody (3465, Cell Signaling Technology) before staining with propidium iodide. Cells were analyzed using FACSort flow cytometer and CellQuest Pro (Becton Dickinson).
Patients
A total of 244 high-risk ER+ postmenopausal patients diagnosed with breast cancer between 1989 and 2001 were included in this study. They had all received tamoxifen as first-line adjuvant endocrine treatment according to the guidelines from the Danish Breast Cancer Cooperative Group. 55 Further details on patients and tumor material have been published previously. 8 Analyses of the clinical material have been approved by the local ethics committee (S-VF-20040064).
Immunohistochemistry
Immunohistochemistry was carried out on tissue microarrays using a standard immunoperoxidase procedure. 8, 56, 57 In brief, antigen retrieval was performed by microwaving the slides for 15 min in 10 mM Tris-base, 1 mM EDTA, pH 9.0. Endogenous peroxidase activity was quenched by 3% hydrogen peroxide and non-specific binding blocked by serum-free protein block (Dako). Aurora kinase A antibody (Cell Signaling Technologies; 4718) was diluted 1:100 and applied overnight at 4°C. Envision (Dako) was used for signal amplification and 3,3-diaminobenzidine tetrahydrochloride (Vector Laboratories, Burlingame, CA, USA) was used to detect positive samples. Nuclei were counterstained with hematoxylin before mounting in pertex (Histolab, Göteborg, Sweden). Protein expression was evaluated in two cores from each tumor and the mean values of the percentage of positive cells were used for statistical analyses.
Statistical analyses
Group comparisons were done using a two-tailed t-test with Bonferroni adjusted P-values for multiple testing. To investigate the effect of expression level of Aurora kinase A on disease-free and overall survival, we used a Cox proportional hazards model to estimate the hazard ratios.
To avoid any linear misspecification, a restricted cubic spline for the scores was used in the model. Both uni-and multivariate analyses were performed. The multivariate analysis included the following standard covariates-tumor grade, size and nodal status. Kaplan-Meier life tables with log-rank testing were plotted to assess the influence of Aurora kinase A on disease-free and overall survival. All analyses were performed in R version 3.0.1 with the R package 'rms'. Po0.05 was considered statistically significant.
